Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 11/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.53 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.51 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
| ▸ | IL1B | P01584 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321176 | 0.87 | SLC9A1 (0.47) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6312274 | 0.86 | SLC9A1 (0.51) | KEAP1NFE2L2SLC9A1SLC9A2OPRM1 | |
| Hydrochloric Acid SCHEMBL6320675 | 0.85 | SLC9A1 (0.72) | KEAP1NFE2L2SLC9A1SLC9A2OPRM1 | |
| Hydrochloric Acid SCHEMBL6319935 | 0.84 | SLC9A1 (0.51) | KEAP1NFE2L2SLC9A1SLC9A2OPRM1 | |
| SCHEMBL6314770 | 0.81 | NR4A3 (0.54) | SLC9A1MALT1IL1BTP53 | |
| SCHEMBL6262880 | 0.81 | SLC9A1 (0.74) | KEAP1NFE2L2SLC9A1SLC9A2OPRM1 | |
| Hydrochloric Acid SCHEMBL7686352 | 0.80 | SLC9A1 (0.74) | KEAP1NFE2L2SLC9A1SLC9A2OPRM1 | |
| SCHEMBL20265392 | 0.79 | MALT1 (0.62) | SLC9A1MALT1IL1B | |
| SCHEMBL6312530 | 0.77 | SLC9A1 (0.62) | KEAP1NFE2L2SLC9A1SLC9A2OPRM1 | |
| SCHEMBL6321480 | 0.77 | TP53 (0.47) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | claimed |
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6555570-B2 | Growth hormone secretagogous with improved bioavailability | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6127391-A | A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | KEAP1 313/4885NFE2L2 450/4885SLC9A1 5/4885 |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, GRPR | KEAP1 3920/4885NFE2L2 2401/4885SLC9A1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.